Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients — Stella

Home/Neovascular Age-related Macular Degeneration/Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

View on ClinicalTrials.gov

Recruiting

Back to Neovascular Age-related Macular Degeneration trials

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Key details

Phase

Very early testing

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborators

Innostellar Biotherapeutics Co.,Ltd

Enrollment target

~10 participants

Started

July 2025

Primary completion

November 2026

Age range

50 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.